Results 41 to 50 of about 46,363 (226)

Population Pharmacokinetics and Exposure–Response Analyses of Momelotinib, Its Active Metabolite (M21), and Total Active Moiety in Myelofibrosis

Clinical Pharmacology &Therapeutics, EarlyView.
Momelotinib, a Janus kinase (JAK) 1/JAK2/activin A receptor type 1 inhibitor, is approved for the treatment of myelofibrosis with anemia. These analyses characterized the population pharmacokinetics of momelotinib and its active metabolite M21 following administration of the commercial tablet formulation in patients with myelofibrosis from phase II/III
Benjamin Rich, Meenakshi Srinivasan, Yu Liu Ho, Sandra A.G. Visser, Geraldine Ferron‐Brady, Georgios Vlasakakis   +5 more
wiley   +1 more source

Correlation of cytogenetics and grade of bone marrow fibrosis in primary myelofibrosis [PDF]

Srpski Medicinski Časopis Lekarske Komore
Introduction/Aim: Primary myelofibrosis is a clonal myeloproliferative neoplasm characterized by bone marrow fibrosis and extramedullary hematopoiesis.
Đorđević Vesna, Peruničić-Jovanović Maja, Šefer Dijana, Bižić-Radulović Sandra, Soldatović Ivan, Todorović-Balint Milena   +5 more
doaj   +1 more source

Use of ropeginterferon in inducing graft versus myelofibrosis effect in post‐transplant myelofibrosis relapse

Clinical Case Reports, 2023
Key Clinical Message Here, we describe a patient with post‐transplant myelofibrosis with chronic graft‐versus‐host disease (GVHD), who showed successful molecular remission with ropeginterferon with 100% donor chimerism without any flare up of GVHD.
Barnali Srivastava, Christine Wolschke, Nico Gagelmann, Anita Badbaran, Nicolaus Kröger   +4 more
doaj   +1 more source

Mutant calreticulin knockin mice develop thrombocytosis and myelofibrosis without a stem cell self-renewal advantage. [PDF]

, 2018
Somatic mutations in the endoplasmic reticulum chaperone calreticulin (CALR) are detected in approximately 40% of patients with essential thrombocythemia (ET) and primary myelofibrosis (PMF).
Aungier, Juliet, Bennett, Cavan, Dovey, Oliver M, Ghevaert, Cedric, Gonzalez-Arias, Carlos, Green, Anthony R, Grinfeld, Jacob, Hamilton, Tina L, Kent, David G, Klampfl, Thorsten, Li, Juan, Loughran, Stephen, Park, Hyun Jung, Pask, Dean C, Prins, Daniel, Sneade, Rachel, Vassiliou, George S, Williams, Matthew   +17 more
core   +1 more source

Cystatin C‐based eGFR better predicts renal vancomycin clearance than creatinine‐based eGFR in patients with allogeneic stem cell transplantation

Clinical Pharmacology &Therapeutics, EarlyView.
Knowledge of the glomerular filtration rate (GFR) is mandatory when dosing renally eliminated drugs such as vancomycin. In clinical practice, different biomarkers and various equations are used to estimate GFR (eGFR), resulting in varying estimates.
Eva‐Maria A. Wansing, Sebastian G. Wicha, Peter Bannas, Alexander Heitkamp, Adrin Dadkhah, Nicolaus M. Kröger, Isabel Molwitz, Claudia Langebrake   +7 more
wiley   +1 more source

Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes

Haematologica, 2011
Background The myeloproliferative neoplasms, essential thrombocytosis, polycythemia vera and primary myelofibrosis, share the same acquired genetic lesion, but the concept of JAK2 V617F serving as the sole lesion responsible for these neoplasms is under ...
Brady L. Stein, Donna M. Williams, Christine O’Keefe, Ophelia Rogers, Roxann G. Ingersoll, Jerry L. Spivak, Amit Verma, Jarek P. Maciejewski, Michael A. McDevitt, Alison R. Moliterno   +9 more
doaj   +1 more source

Ruxolitinib in the treatment of polycythemia vera: patient selection and special considerations. [PDF]

, 2016
The discovery of JAK2 V617F mutation in the mid-2000s started to fill the gap between clinical presentation of polycythemia vera (PV), first described by Vaquez at the end of the 19th century, and spontaneous erythroid colony formation, reported by ...
Alberio, L., Blum, S., Martins, F.
core   +2 more sources

European Bone Marrow Working Group trial on reproducibility of World Health Organization criteria to discriminate essential thrombocythemia from prefibrotic primary myelofibrosis

Haematologica, 2012
Background The World Health Organization classification of myeloproliferative neoplasms discriminates between essential thrombocythemia and the prefibrotic phase of primary myelofibrosis.
Thomas Buhr, Konnie Hebeda, Vassiliki Kaloutsi, Anna Porwit, Jon Van der Walt, Hans Kreipe   +5 more
doaj   +1 more source

The degree of anisocytosis predicts survival in patients with primary myelofibrosis [PDF]

, 2016
Introduction: Red cell distribution width (RDW) provides a quantitative measure of anisocytosis and it is associated with the presence of subclinical systemic inflammation and a poor outcome in a variety of diseases when elevated.
Hariš, Višnja, Jakšić, Ozren, Kušec, Rajko, Lucijanić, Marko, Mitrović, Zdravko, Pejša, Vlatko, Piršić, Mario, Prka, Željko, Tomasović-Lončarić, Čedna, Vasilj, Tamara, Štoos-Veić, Tajana   +10 more
core   +1 more source

Ruxolitinib in cytopenic myelofibrosis: Response, toxicity, drug discontinuation, and outcome [PDF]

, 2023
Francesca Palandri, Massimo Breccia, Camilla Mazzoni, Giuseppe Auteri, Elena Maria Elli, Malgorzata Monika Trawinska, Nicola Polverelli, Mario Tiribelli, Giulia Benevolo, Alessandra Iurlo, Alessia Tieghi, Florian H. Heidel, Giovanni Caocci, Eloise Beggiato, Gianni Binotto, Francesco Cavazzini, Maurizio Miglino, Costanza Bosi, Monica Crugnola, Monica Bocchia, Bruno Martino, Novella Pugliese, Mattia Biondo, Marta Venturi, Luigi Scaffidi, Alessandro Isidori, Daniele Cattaneo, Mauro Krampera, Fabrizio Pane, Daniela Cilloni, Gianpietro Semenzato, Roberto M. Lemoli, Antonio Cuneo, Elisabetta Abruzzese, Daniela Bartoletti, Simona Paglia, Nicola Vianelli, Michèle Cavo, Massimiliano Bonifacio, Giuseppe A. Palumbo   +39 more
openalex   +1 more source